Susquehanna Fundamental Investments LLC Acquires New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Susquehanna Fundamental Investments LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 4,518 shares of the biopharmaceutical company's stock, valued at approximately $216,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of HALO. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at $29,000. CBIZ Investment Advisory Services LLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $29,000. Smartleaf Asset Management LLC increased its position in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust boosted its holdings in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares in the company, valued at $2,120,567.40. The trade was a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,697 shares of company stock worth $1,276,552 in the last three months. Corporate insiders own 2.40% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on HALO. Benchmark reiterated a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. JPMorgan Chase & Co. raised their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. HC Wainwright reissued a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Friday, April 25th. Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Finally, Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $62.89.

Halozyme Therapeutics Price Performance

HALO stock opened at $61.19 on Monday. The company has a fifty day simple moving average of $60.79 and a two-hundred day simple moving average of $55.41. Halozyme Therapeutics, Inc. has a 52 week low of $40.19 and a 52 week high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm has a market capitalization of $7.56 billion, a P/E ratio of 17.84, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.